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Groupe Hospitalier Cochin Saint-Vincent de Paul, Unité d’Hépatologie, FranceTransplantation is the best treatment for end-stage organ fail- regression of cirrhosis, which in turn may lead to decreased dis-
ure. Hepatitis virus infections, mainly hepatitis B virus (HBV) and
hepatitis C virus (HCV) infections still constitute a major problem
because they are common in allograft recipients and are a signif-
icant cause of morbidity and mortality after transplantation.
Recently, hepatitis E virus infection has been added as an emer-
gent cause of chronic hepatitis in organ transplantation. The
prevalence of HBV and HCV infections has markedly decreased
in patients who are candidates for transplantation since the
introduction of screening, hygiene and prevention measures,
including systematic screening of blood and organ donations,
use of erythropoietin, compliance with universal hygiene rules,
segregation of HBV-infected patients from non-infected patients
and systematic vaccination against HBV. A liver biopsy is prefer-
able to non-invasive biochemical and/or morphological tests of
ﬁbrosis to evaluate liver ﬁbrosis before and even after transplan-
tation. Treatment with entecavir or tenofovir is indicated in HBV-
infected dialyzed patients who have moderate or severe disease
(PA2 or F2 on the Metavir scale) in preparation for renal trans-
plantation. Due to the risks of severe reactivation, ﬁbrosing chole-
static hepatitis or histological deterioration after transplantation,
systematic use of nucleoside or nucleotide analogues shortly
before or at the time of transplantation is recommended (tenofo-
vir or entecavir are preferable to lamivudine) in all patients,
whatever the baseline histological evaluation. In HCV-infected
dialyzed patients who are not candidates for renal transplanta-
tion, the indication for antiviral therapy is limited to signiﬁcant
ﬁbrosis (ﬁbrosis P2 on the Metavir scale). Treatment must be
proposed to all candidates for renal transplantation, whatever
their baseline histopathology, and interferon-a should be used
as monotherapy. After transplantation, interferon-a is contrain-
dicated but may be used in patients for whom the beneﬁts of
antiviral treatment clearly outweigh the risks, especially that of
allograft rejection. All cirrhotic patients, notably after solid organ
transplantation, should be screened for hepatocellular carcinoma.
Sustained suppression of necro-inﬂammation may result inJournal of Hepatology 20
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E-mail address: stanislas.pol@cch.aphp.fr (S. Pol).ease-related morbidity and improved survival. Finally, due to the
high mortality after renal transplantation, active (namely without
sustained viral suppression) cirrhosis should be considered a con-
traindication to kidney transplantation, but an indication to com-
bined liver-kidney transplantation; on the contrary, inactive
(namely with sustained viral suppression) compensated cirrhosis
may permit renal transplantation alone.
Organ transplantations other than kidney (cardiac or pulmon-
ary transplantations) involve the same diagnosis and therapeutic
issues.
 2011 European Association for the Study of the Liver. Published
by Elsevier B.V. All rights reserved.
Introduction
Solid organ transplantation is the best way to treat organ failure.
Tremendous progress has been made in the transplantation set-
ting over the last two decades, mainly related to the improve-
ment of surgical techniques, immunosuppressive regimens
(more potent and less toxic) and diagnosis and treatment of
infections. Nevertheless, immunosuppressive therapies for the
prevention of graft rejection after transplantation enhance the
risk of infections and modify their natural history. Hepatitis virus
infections, mainly hepatitis B virus (HBV) and hepatitis C virus
(HCV) infections, still constitute a major problem because they
are common in allograft recipients and are a signiﬁcant cause
of morbidity and mortality after transplantation. Recently, hepa-
titis E virus (HEV) infection has been added as an emergent cause
of chronic hepatitis in organ transplantation.
We will discuss viral hepatitis (HBV, HCV and HEV) infections
in solid organ transplantation other than liver transplantation,
with a particular focus on kidney transplantation, which has
the same diagnosis and therapeutic issues as cardiac or pulmon-
ary transplantations. In kidney transplant recipients, the priori-
ties of treatment include renal function and immune
suppression, rather than potential hepatitis-related liver prob-
lems. However, efﬁcient management of viral infections is
required to avoid a harmful impact on the patient due to liver-
related mortality and to promote allograft survival; indeed,
HBV and HCV may induce de novo membranous glomerulone-
phritis, causing renal function impairment that may lead to graft
loss [1].11 vol. 55 j 474–482
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What is already known
Epidemiology
Hepatitis B virus
Hepatotropic viral infections, including HBV, are more frequent
in renal transplant recipients and dialysis patients than in the
general population and have a signiﬁcant impact on the survival
of these patients [2–5]. Viral hepatitis is reported in about 15–
20% of heart transplant recipients [6–9].
The prevalence of HBV infection in dialyzed patients is around
0–10% in industrialized countries and 2–20% in developing coun-
tries (it was around 45% before the anti-HBV vaccination era)
[2,3]. This high prevalence can be explained by the epidemiology
of HBV – especially the parenteral mode of transmission of the
virus. Contamination may be secondary to blood transfusions
used in the treatment of anemia due to chronic renal failure,
transfusion protocols in preparation for renal transplantation,
nosocomial contamination (dialysis) or transplantation of an
infected renal transplant from an HBsAg-positive or anti-HBc
antibody donor [10,11]. With the systematic screening of blood
products for HBV, the risk of transmission of HBV has markedly
decreased (see below) but, nevertheless, HBV is still the most fre-
quent blood-borne infection (1/700,000).
Hepatitis C virus
HCV infection is more frequent in renal transplant recipients and
dialysis patients than in the general population and has a signif-
icant impact on the survival of these patients [1,4,5,12–15]. HCV
infection is frequent in hemodialyzed patients, with a prevalence
ranging between 10% and 65% according to the geographical
zone. The prevalence is signiﬁcantly correlated with the duration
of hemodialysis and the number of units of blood products trans-
fused [13]. The annual incidence of HCV infection in hemodialysis
ranges from 0% to 2.4%. Inter-human transmission (possibly
hand-borne by personnel) or transmission by contaminated med-
ication vials are the main routes of contamination in hemodialy-
sis centers. HCV transmission is predominantly related to failure
to comply with universal hygiene rules; compliance with univer-
sal hygiene rules has eliminated nosocomial transmission of HCV
[14], and transmission by dialysis equipment per se is today anec-
dotal [16]. Isolation of HCV-infected patients or the use of dedi-
cated dialysis machines are not recommended [17].
In heart transplant patients, the prevalence of HCV – mainly
transmitted by transfusion or heart donation – is about 11–16%
[6–8].
Hepatitis E virus
HEV is considered to be responsible for acute hepatitis that does
not become chronic [18,19]. HEV infection is endemic in several
developing countries with a preferential fecal-oral mode of trans-
mission. In recent years, a growing number of cases of HEV infec-
tion have been reported in industrialized countries with a
zoonotic mode of transmission (undercooked pig meat consump-
tion). Anti-HEV IgG antibodies are present in 16.6% of blood
donors in France [20] and in 6–16% of renal transplant recipients
[21]. HEV is a newly recognized cause of chronic liver disease in
immunocompromised hosts – including kidney and liver trans-
plant recipients [21–24]. There are no published data on HEV in
heart or lung transplant recipients.Journal of Hepatology 201Preventive treatments
Hepatitis B virus
The prevalence of HBV infection has markedly decreased in
patients with renal impairment since the introduction of screen-
ing, hygiene and prevention measures. Systematic screening of
blood and organ donations has reduced the risk of transmission
by blood transfusions or organ transplantation, and compliance
with universal hygiene rules as well as the segregation of HBV-
infected patients and non-infected patients at the beginning of
the 1980s has dramatically reduced the nosocomial risk of trans-
mission of HBV, at least in industrialized countries [25]. In addi-
tion, the number of blood transfusions has decreased with the
use of erythropoietin. Systematic vaccination of all renal failure
patients is the best preventive treatment of HBV infection [26].
However, vaccine immunogenicity is low in dialyzed patients
(around 70%) and even lower in renal transplant recipients
(30%) as compared to 90% in the general population. That is
why vaccination must be performed early in the history of renal
failure, preferably before starting dialysis [26]. Factors related to
a poor vaccine response are also observed in renal patients; these
factors can be acquired, such as ageing, or genetic, such as gender
or the HLA A1B8DR3 ‘‘non-responder’’ haplotype. When the stan-
dard protocol is ineffective, the use of intensiﬁed protocols or
intradermal injections can reinforce immunogenicity in hemodi-
alyzed patients [27,28]. On the contrary, the use of nonspeciﬁc
immunostimulation (by interleukin 2, for example) does not
improve the efﬁcacy of vaccination [29,30]. Finally, booster vacci-
nations can play an important role in improving immunogenicity,
even in the absence of response to primary immunization: a
booster injection in renal transplant recipients, vaccinated while
on hemodialysis, has a global efﬁcacy of 84% [30]. We recom-
mend booster vaccine injections every 3–5 years in these popula-
tions of poor-responder patients potentially exposed to HBV.
Peculiarities exist concerning the epidemiology of HBV infection
in cardiac allograft recipients, since contamination occurs mainly
after transplantation and is related to nosocomial infection asso-
ciated with the use of cardiac myotomes for myocardial biopsies
[31]. Active HBV vaccination is mandatory before heart
transplantation.
Hepatitis C virus
The prevalence of HCV infection has decreased signiﬁcantly since
the introduction of various preventive measures [14]: systematic
screening of blood and organ donations, use of erythropoietin and
compliance with universal hygiene rules. Nevertheless, HCV con-
tamination persists in the dialysis setting, with a current inci-
dence of 0–2.4% per year depending on the center, mainly via
nosocomial transmission [25]. In a prospective study, the inci-
dence of seroconversion decreased from 0.65% to 0% after stricter
compliance with universal hygiene rules, without any change in
the number of blood products or the equipment disinfection
techniques after each dialysis session [14]. The KDIGO clinical
practice guidelines do not recommend isolation of HCV-infected
patients or the use of dedicated dialysis machines for HCV-
infected patients as an alternative to strict infection-control pro-
cedures for preventing transmission of blood-borne pathogens
[17]. The same preventive measures decrease the prevalence of
HCV in heart transplant recipients. No HCV vaccine is available
at the present time.1 vol. 55 j 474–482 475
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Hepatitis E virus
An effective vaccine against HEV is under development but is not
yet available [21,32]. The prevention of transmission of HEV is
based on respect of hygiene rules, including the adequate cooking
of meat. There is no systematic screening of HEV infection for
blood donation. Although cases of blood-born transmission of
HEV have been described, the risk of parenteral transmission
appears to be very low, as for hepatitis A virus [33].
Impact of transplantation on the natural history of hepatitis
Hepatitis B virus
Most studies showahighermortality in renal transplant recipients
infected with HBV, compared with renal transplant recipients
without HBV infection, although this topic is still under debate
[34–36]. This highermortality is related to liverdisease and is asso-
ciated with a more frequent andmore rapid progression to cirrho-
sis and hepatocellular carcinoma, probably because the
immunosuppressive regimen enhances viral replication [37,38].
Cases of hepatitis rapidly evolving to hepatocellular insufﬁciency
and death within several weeks have been described in patients
treatedwith immunosuppressive agents [39]. These cases of ﬁbro-
sing cholestatichepatitis aredue tohepatocytedysfunction related
to the accumulationof viral antigen in cisternae of the endoplasmic
reticulum secondary to intense viral replication [40]. Inmost stud-
ies, graft survival is also lower in HBV-infected patients, with renal
impairment manifested as ascitis.
Contradictory results concerning the long-term outcomes of
HBV infection in heart transplant recipients have been reported.
Some authors have described a poor outcome, with cirrhosis
occurring in more than 55% of patients within the ﬁrst decade
after transplantation, and 17% of patients dying of liver failure
[9]. Others have reported little impact on short- or long-term sur-
vival [8].
Hepatitis C virus
HCV infection in renal transplant recipients is associated with a
signiﬁcant reduction in patient and graft survival due to liver dis-
ease or septic complications related to cirrhosis and immunosup-
pressive therapy [37,38,41]. The immunosuppressive regimens
prescribed after transplantation modify the natural history of
chronic HCV infection, leading to an earlier onset of cirrhosis
and its complications [41]. It is noteworthy that some reports
do not clearly indicate that immunosuppressive drugs stimulate
ﬁbrosis progression [42,43]; these discrepancies may be
explained by the use of different immuosuppression protocols.
Life expectancy of HCV-infected dialysis patients is nevertheless
better after renal transplantation than when dialysis is continued
[44]. In our experience, compared with renal transplant recipi-
ents, dialysis patients have a ﬁvefold lower viremia and a lower
rate of cirrhosis (10% versus 25–40%; personal data). Lastly,
underlying chronic viral liver disease increases the risk of hepato-
toxicity during treatment with azathioprine [45].
Decreased long-term survival in heart transplant recipients
that have HCV infection has not been described [8,46,47].
Increased incidence of hepatocellular carcinoma (HCC) in solid organ
transplantation
An elevated incidence of HCC might be expected in solid organ
recipients, given the high prevalence of HCV and HBV infections476 Journal of Hepatology 201and the possible contribution of immunosuppression. A recent
study using registry data (223,660 recipients between 1987 and
2005) reported an HCC incidence arising after transplant of 6.5
per 100,000 person-years among kidney, heart and lung recipi-
ents, and 25 per 100,000 person-years among liver recipients,
which was similar to that of the general population but elevated
among recipients with HCV and HBV. HCC risk was associated
both with HCV antibody (HR 6.9, 95% CI 2.5–19) and with HBsAg
(HR 9.7, 95% CI 2–33) [48]. In our experience, HCC rapidly evolves
in transplant recipients and other immunocompromised patients
[49]. Therefore, after solid organ transplantation, early screening
with an abdominal ultrasound (every 3 months in cirrhotic
patients and every 6–12 months in non-cirrhotic patients) is nec-
essary when risk factors such as HBV or HCV are present [48].
New concepts
Major progress has been made over the last 10 years in the treat-
ment of HBV and HCV infections. Viral hepatitis requires the
same management in organ recipients as in the general popula-
tion. There are no speciﬁc criteria for the serologic or virologic
diagnosis of infection, but occult infection may be more frequent
and the higher viral load may impact on the severity of the liver
disease. Serial evaluation of the impact of hepatitis on the liver
(stage and grade) is mandatory in allograft recipients. A liver
biopsy [50,51] and biochemical or morphological non-invasive
tests (such as elastometry) may be performed for ﬁbrosis evalu-
ation, although further studies are required to conﬁrm the rele-
vance of the latter procedures in this setting [52–55].
Recommendations for HBV therapy (Fig. 1)
Lamivudine has historically occupied an important place [56,57].
Since it is essentially eliminated by the kidney, its dosage must be
adapted to renal function. The recommended dose is 100 mg/day
in renal transplant recipients with creatinine clearance >50 ml/
min. The efﬁcacy of this treatment is limited by the occurrence
of: (1) reactivation if treatment is discontinued; (2) break-
through, deﬁned by reappearance of viral replication, despite
continuation of treatment to avoid reactivation [57]. Severe
forms of exacerbation have been described during reactivation
or virologic breakthrough. In the case of resistance to lamivudine,
the only therapeutic alternatives are adefovir dipivoxil and ten-
ofovir. The dosage of all nucleoside and nucleotide analogues
has to be adapted to the patient’s renal function [58]. Adapted
dosages avoid the risks of tubular dysfunction and are effective.
The only published results of adefovir in treatment-naive or lam-
ivudine-resistant renal patients can be summarized as follows: (i)
antiviral potency with a median reduction in viral load of 4.5
log copies/ml after 52 weeks of treatment; (ii) absence of nephro-
toxicity with improvement of proteinuria, stable serum creati-
nine and creatinine clearance after treatment lasting an average
of 20 months in 10 renal transplant recipients and 2 hemodia-
lyzed patients [59]. The possibility of reactivation or resistance
requires careful evaluation of the indication of lamivudine or ade-
fovir in patients with minimal lesions.
Nucleos(t)ide analogues like entecavir or tenofovir are now
recommended in the general population for the treatment of
chronic HBV infection. They are more potent and have a higher
genetic barrier than lamivudine or adefovir. One recent study
has focused on entecavir therapy in 10 male transplant patients1 vol. 55 j 474–482
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Fig. 1. Treatments of HBV infection in renal disorders.
JOURNAL OF HEPATOLOGY(8 had received kidney transplants) who had become resistant to
adefovir or lamivudine [60]. All patients experienced a decrease
in HBV DNA with no change in renal function or hematological
parameters. In the general population, data regarding entecavir
show that, while the risk of resistance is low in treatment-naive
patients, it may be as high as 51% at 5 years in lamivudine-resis-
tant patients. Tenofovir is more effective than adefovir in the
non-renal transplant population, is effective in lamivudine-resis-
tant patients and does not lead to resistance after 4 years of treat-
ment [61–63]. Tenofovir has a much lower renal toxicity than
adefovir and should be preferred in kidney transplant recipients.
The KDIGO guidelines recommend that all HBsAg-positive kidney
transplant recipients receive prophylaxis with tenofovir, enteca-
vir or lamivudine; however, tenofovir and entecavir are prefera-
ble to lamivudine to minimize the development of drug
resistance [64]. Lamivudine-resistant patients have to be treated
with tenofovir or adefovir [64]. The EASL guidelines recommend
that all HBsAg-positive patients who are candidates for solid
organ transplantation are treated with nucleos(t)ide analogues
[65]. Anti-HBcore positive HBsAg-negative patients and unde-
tectable HBV DNA should be followed carefully by means of
ALT and HBV DNA testing each 3 months and should be treated
with analogues upon conﬁrmation of HBV reactivation before
ALT elevation.
The variations in immune status observed at the time of
induction of immunosuppression or during reduction of immu-
nosuppression during the ﬁrst months after transplantation carry
a risk of two potentially fatal mirror events: (1) HBV viral reacti-
vation, which may result in severe hepatitis (ﬁbrosing cholestatic
hepatitis or fulminant hepatitis); (2) immune restoration leading
to rapid clearance of infected hepatocytes with spontaneous
arrest of viral multiplication, which may have severe conse-
quences (fulminant hepatitis). In view of these risks, all HBsAg-
positive patients with variations in their immune status should
be evaluated with quantiﬁcation of HBV DNA and ﬁbrosis, andJournal of Hepatology 201be given the so-called pre-emptive therapy [66]. The date of ini-
tiation (inscription on waiting lists, after a deﬁned time on the
waiting list as a function of blood group or at the time of
transplantation) is not yet deﬁned. Patients should receive pre-
emptive treatment with nucleos(t)ide analogues during immuno-
suppressive therapy, regardless of HBV DNA levels, and treatment
should be continued as long as the immunosuppressive therapy
lasts. Most experience with pre-emptive treatment has been
reported with lamivudine [66].
In summary, all HBsAg-positive candidates for transplantation
and all transplant recipients should receive antiviral therapy with
nucleos(t)ide analogues to maintain HBV DNA negative. Viral
suppression by inhibiting necro-inﬂammation may result in
reduced ﬁbrosis, thereby improving transplant survival.
Recommendations for HCV therapy (Fig. 2)
In the general population, the reference treatment for HCV infec-
tion is currently dual therapy with pegylated interferon-a and
ribavirin, which ensures sustained virological response (SVR),
corresponding to viral eradication, in 50% of cases [67].
For pharmacokinetic reasons, accumulation of ribavirin
metabolites in erythrocytes and erythroblasts during treatment
can enhance anemia due to renal failure by exacerbation of riba-
virin-associated hemolytic anemia. Consequently, there is a risk
of severe and prolonged anemia refractory to recombinant eryth-
ropoietin [68]. Therefore, ribavirin is contraindicated in chronic
renal failure patients with creatinine clearance of less than
50 ml/min [69,70]. For HCV-infected patients on maintenance
hemodialysis, the KDIGO guidelines suggest monotherapy with
standard interferon that is dose-adjusted for a GFR of <15 ml
per min per 1.73 m2 [17]. Interferon-a (standard, consensus or
pegylated) can also be used in combination with a low dose
(200 mg) of ribavirin daily [71] or after each dialysis session, with
an increased dosage of erythropoietin. In our own experience,1 vol. 55 j 474–482 477
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Fig. 2. Treatments of HCV infection in renal disorders. ⁄All HCV-infected patients who are candidates for renal transplantation should be offered an antiviral treatment.
Frontiers in Liver Transplantationincreased rates of SVR were not observed in patients receiving
combination therapy compared with those receiving consensus
interferon alone. In addition to the adverse effects classically
associated with interferon-a in patients without CRF, dialysis
patients may experience severe adverse effects, specially cardio-
vascular effects such as symptomatic cardiomyopathies and
angina, ophthalmologic disorders, and hemorrhagic strokes. In
turn, ribavirin may increase the severity of side effects, resulting
in blood transfusions (47%) or ribavirin discontinuation, a high
drop-out rate (71.4%) or death (2/15) [71]. In dialysis patients,
interferon-a is used as monotherapy according to standard regi-
mens: 3 million units of standard interferon-a or 9 lg of consen-
sus interferon by self-administered subcutaneous injection 3
times a week after each dialysis session for 6–12 months (possi-
bly decreased to 1.5 MU if there are adverse effects) [72–76] or
135 (or 90) lg of pegylated interferon by subcutaneous injection
once a week [77]. The main studies that have investigated treat-
ment of HCV infection in dialysis patients are summarized in
Table 1.
In patients waiting for transplantation, histological examina-
tion is mainly designed to detect cirrhosis, which contraindicates
kidney transplantation because of the risk of fatal progression of
cirrhosis following transplantation. In this case, combined liver-
kidney transplantation must be considered. The severity of hepa-
tic lesions should be evaluated by a liver biopsy allowing semi-
quantitative histological scores. The aim of antiviral therapy in
patients waiting for renal transplantation is viral eradication,
regardless of the histological stage, in order to improve the prog-
nosis after transplantation by decreasing the risk of post-trans-
plantation liver-related mortality and de novo HCV-related
proliferative glomerulonephritis. Early viral kinetics allow rapid
discontinuation if the treatment is ineffective [72]. In hemodia-
lyzed patients presenting with acute hepatitis C (often marked
by moderate elevation of transaminases and GGT), monotherapy478 Journal of Hepatology 201with standard interferon (3 MU after each dialysis session for
6 months) or pegylated interferon is strongly recommended. In
compensated cirrhotic patients who achieve an SVR [78], liver
cirrhosis may be reversible and baseline cirrhosis should not be
considered as an absolute contraindication to transplantation.
An SVR to interferon is achieved in around 40% of dialysis
patients. There is no virologic relapse after transplantation
[79,80]. Following renal transplantation, interferon- (standard
or pegylated) is contraindicated because of (i) low long-term efﬁ-
cacy (probably due to the presence of two factors of poor
response: high frequency of genotype 1b and high viremia);
and (ii) a risk of graft rejection close to 50% and 60% [81]. These
patients therefore must resume hemodialysis. Ribavirin mono-
therapy frequently restores normal transaminase levels and
sometimes lowers viremia, but without suppressing viral replica-
tion [82]. Contradictory results have been reported concerning
hepatic histopathological improvement, improvement of renal
function and reduction of proteinuria [83,84]. The potential ben-
eﬁcial effects of ribavirin might be due to the immunomodulatory
properties. Therefore, in the absence of other available treat-
ments and due to its acceptable safety proﬁle, ribavirin mono-
therapy may be considered in renal transplant recipients with
extensive ﬁbrosis, while waiting for the development of new
antiviral therapeutic strategies. In this setting, ribavirin should
be prescribed cautiously at increasing doses (200 mg/month
increased to effective doses of 800–1000 mg/day) due to the high
risk of anemia, accentuated by concomitant treatment with aza-
thioprine or mycophenolate mofetil. Another approach, described
in a pilot study, indicates that a combination of very low-dose
interferon- (interferon-a-2a 1  106 units  3/week) and ribavi-
rin (600 mg/day) has biochemical and virological efﬁcacy in renal
transplant recipients, apparently not accompanied by an
increased risk of graft rejection [85]. These results have yet to
be conﬁrmed.1 vol. 55 j 474–482
Table 1. Studies of anti-HCV treatments in dialysis patients.
Mousa et al.
Rivera et al.
Sikole et al.
van Leusen et al.
Carriero et al.
Celal et al.
Akhan et al.
Kose et al.
Djekova et al.
Alsaran et al.
Peck-Radosavljevic et al.
Total 
Transplant Proc 2004
Transplant Proc 2005
Ren fail 2007
Nephrol Dial 
Transplant 2008
Int J Artif Organs 2008
World J 
Gastroenterol 2008
Infection 2008
J Gastroenterol 2009
Int J Artif Organs 2009
Int Urol Nephrol 2010
Clin Gastroenterol 
Hepatol 2010
INF + RBV
INF  (n = 20) 
Peg INF (n = 7)
Peg INF
Peg INF +
RBV
Peg INF +
RBV
Prospective study
Peg INF, Prospective 
controlled study
Peg INF 
Peg INF 
Peg INF
Peg INF
(+ RBV in 3 patients)
Peg INF
135
90
20/G1 and 4
27/G1b
14
5/G1 
2/G2 
14
12/G1 
22/G1 
12  
33
14
13
29/G1
9/non G1
32/G1 
11/non G1
267
24/27
9/14
7/7
7/14
17/22
12/12
26/33
14/14
13/13
28/38
32/43
209/267
n = 9 24 w
n = 11 48 w
48 w
48 w
48 w
24 w
48 w
48 w
48
48
48 w
48 w 
66%
55%
40.7%
36%
60%
100%
28.6%
64.7%
50%
78.8%
37.5%
69%
31%
66.7%
37.5%
27.3%
27.3 to 78.8
NS
3/27 (12%) pancytopenia
3/14 Pneumonia, pericarditis,
1 death due to cerebral 
hemorrhage
Reduction  of peg dosage
4 red cell transfusions
2 deaths due to cardio-vascular 
disease anemia
5/22
Weakness, anemia, bleeding
Thrombopenia
Anemia, thrombopenia
Reduction of dosage
3 deaths, 6 SAE 
5 SAE
Authors Journal Treatment Number of 
patients/
genotype (G)
Completed
treatment
Duration of
treatment
SVR Adverse events
JOURNAL OF HEPATOLOGYFinally, for HCV-infected kidney transplant recipients in
whom the beneﬁts of antiviral treatment clearly outweigh the
risks, the KDIGO guidelines suggest monotherapy with standard
interferon [64].
It has been suggested that, at least theoretically, mycopheno-
late mofetil could have an antiviral effect on HCV since, like riba-
virin and other nucleoside analogues under development, it
inhibits the IMPDH (inosine monophosphate dehydrogenase)
pathway involved in viral replication. However, a study provided
evidence against this hypothesis by showing, a signiﬁcant
increase in viremia in HCV-infected renal transplant recipients
treated with this drug [86].
New targeted therapies of HCV infection such as HCV protease
or polymerase inhibitors or cyclophillin inhibitors are not yet
available in the general population. Transplant recipients, in
whom standard HCV therapies have poor efﬁcacy and numerous
adverse effects should be considered as priority patients for these
new drugs.
Recommendations for HEV therapy
Data are currently lacking regarding the treatment of chronic
HEV infection in solid organ transplant recipients. Pegylated
interferon seems to have some efﬁcacy but must be used with
caution because of the risk of graft rejection [87]. Reduction of
immunosuppression can result in undetectability of HEV RNA.
Small studies have reported that ribavirin has promising efﬁcacyJournal of Hepatology 201in immunocompromised patients with chronic HEV infection,
including kidney recipient [88,89]. The optimal dose and duration
remain to be determined in larger studies. In other solid organ
recipients, data are not yet available.
Non-invasive evaluation of ﬁbrosis
Biochemical tests of liver stiffness and ﬁbroscan (elastometry)
are currently used in the general population of HCV mono-
infected patients to replace liver biopsy. These non-invasive
tests have not been validated either in patients with chronic
HBV infection or in solid organ transplant recipients [52–55].
In our experience, the diagnostic accuracy of biochemical non-
invasive markers including Fibrotest, Apri, Forns or FIB-4 index
is still not enough to avoid a liver biopsy in most patients. Liver
stiffness by elastography shares the same limitations. Hence,
liver biopsy remains the gold standard in candidates for trans-
plantation or in transplant recipients. KDIGO guidelines recom-
mend that a liver biopsy is performed in patients on
hemodialysis to evaluate liver disease [17]. Patients who fail
or refuse antiviral treatment should have repeated liver biopsies
every 3–5 years while on the transplant list, depending on their
histo-pathological stage. HCV-infected kidney transplant recipi-
ents (or other solid organ transplant recipients) more than
6 months after transplant should be evaluated at least yearly.
We recommend that a liver biopsy is performed at baseline
and every 3–5 years.1 vol. 55 j 474–482 479
Frontiers in Liver Transplantation
Regression of ﬁbrosis – regression of cirrhosis
Regression of cirrhosis occurs after antiviral therapy in some
HCV- or HBV-infected patients who achieve an SVR or long-last-
ing viral suppression [78,90–92]. Regression is associated with
decreased disease-related morbidity and improved survival
[91]. If a cirrhotic dialysis patient achieves an SVR, a follow-up
liver biopsy should be performed. In the case of reversibility of
cirrhosis, renal transplantation alone is feasible [90]. Patients
with compensated cirrhosis and long-term virologic response
after antiviral therapy against HCV or sustained HBV suppression
by new analogues may be considered for renal transplantation
alone, despite the underlying cirrhosis. On the contrary, com-
bined renal and liver transplantation is the treatment of choice
for those with active cirrhosis.
All patients with cirrhosis (including those before and after
solid organ transplantation) should be screened for early diagno-
sis of HCC at least every 6 months by liver ultrasound evaluation
(with or without alpha-fetoprotein measurement). Given the
high frequency and rapid evolution of HCC in immunocompro-
mised patients, an expert group recommended HCC screening
every 3 months for solid organ transplant recipients with HBV
infection and cirrhosis [65].Conclusion
Patients in a dialysis unit should always be screened for HBV and
HCV as in the general population. Systematic vaccination of all
HBsAg-negative patients is the best preventive treatment of
HBV infection. Testing for HCV RNA with RT-PCR should be
repeated in dialysis patients with unexplained abnormal trans-
aminase levels or if a new HCV infection is suspected (nosocomial
infection).
HBV antiviral therapy should be given to all HBV-infected
dialysis patients who are candidates for renal transplantation –
usually entecavir or tenofovir – in order to reduce the severity
of liver disease and the risk of post-transplant severe reactivation
or ﬁbrosing cholestatic hepatitis. Treatment should be introduced
shortly before or at the time of transplantation in those who are
not already treated for liver disease.
Active HCV infection in a dialysis patient (namely positive
HCV RNA by RT-PCR) requires evaluation of liver ﬁbrosis, prefer-
entially through a liver biopsy. Antiviral therapy should be given
to all HCV-infected dialysis patients in order to achieve an SVR
(synonymous with recovery) not only to avoid subsequent hepa-
tic deterioration but also to limit the risks of HCV-related post-
transplant de novo glomerulonephritis. Interferon must be used
in HCV-infected kidney transplant recipients for whom the bene-
ﬁts of antiviral treatment clearly outweigh the risks. Recent data
suggest that, in renal transplant recipients, the combination of
very low-dose interferon- and ribavirin is effective and is not
accompanied by an increased risk of graft rejection.
Finally, due to the high mortality after renal transplantation,
active cirrhosis is considered a contraindication for kidney trans-
plantation alone, but an indication for combined liver-kidney
transplantation; on the contrary, inactive compensated cirrhosis
may permit renal transplantation alone.
Organ transplantations other than kidney (cardiac or pulmon-
ary transplantations) involve the same diagnosis and therapeutic
issues.480 Journal of Hepatology 201To screen for HBV and HCV infections 
Key points 1 Key messages and recommended 
guidelines in patients who are candidates for solid 
organ transplantation. 
To evaluate the underlying liver disease by performing 
a liver biopsy
Consider antiviral treatment 
- For HBV: systematic use of nucleo(t)side 
analogues (tenofovir and entecavir are preferable 
to lamivudine) shortly before or at the time of 
transplantation (pre-emptive therapy)
- For HCV: standard or pegylated interferon alone 
in dialysis patients (+/- low doses of ribavirin) 
- Active cirrhosis: indication for combined liver/renal 
transplantation
- Inactive compensated cirrhosis: indication for 
solid organ transplantation alon
Cirrhosis
To regularly screen for HCC and portal hypertension in 
cirrhotic patients 
To consider preventive treatments:
 - Vaccination against HBV
 - Respect of universal hygiene rules 
To perform a regular (yearly?) screening of HBV and 
HCV infection 
Key points 2 Key messages and recommended  
guidelines in solid organ transplant recipients.
To consider antiviral treatment
Consider antiviral treatment 
- For HBV: Continued antiviral therapy with 
nucles(t)ide analogues (tenofovir and entecavir 
preferable to lamivudine) to maintain HBV DNA 
negative
- For HCV: Interferon is usually contraindicated in 
renal transplantation but may be used (in combina-
tion with ribavirin) if the benefits outweigh the risks.  
To perform screening of HCC in cirrhotic patients (liver 
ultrasonography every 3 months?)
To evaluate the severity of the underlying liver disease 
by performing a liver biopsy every 3 to 5 yearsConﬂict of interest
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